Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Phase 3

Recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: PF-07220060 CDK4 inhibitor
Drug: Fulvestrant
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2023-10-27

Last Posted Date: 2024-12-13

Lead Sponsor: Pfizer

Target Recruit Count: 500

Registration Number: NCT06105632

Locations: 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇨🇦
CHU de Québec-Université Laval, Hôpital du Saint-Sacrement, Quebec City, Quebec, Canada
🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China

and more 223 locations

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Phase 2

Recruiting

Conditions: HR+/HER2- Advanced Breast Cancer
Targeted Therapy

Interventions: Drug: Everolimus
Drug: Chidamide
Drug: Endocrine therapy
Drug: Ovarian function suppression(OFS)

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 102

Registration Number: NCT05983107

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Phase 3

Recruiting

Conditions: Metastatic Breast Cancer
Mutation
Triple Negative Breast Cancer

Interventions: Drug: Investigator's Choice of Chemotherapy
Drug: Everolimus

First Posted Date: 2023-07-20

Last Posted Date: 2024-01-16

Lead Sponsor: Fudan University

Target Recruit Count: 203

Registration Number: NCT05954442

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Rapalog Pharmacology (RAP PAC) Study

Phase 1

Recruiting

Conditions: Aging

Interventions: Drug: Sirolimus
Drug: Everolimus

First Posted Date: 2023-07-18

Last Posted Date: 2024-05-31

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 72

Registration Number: NCT05949658

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Phase 2

Recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: Fulvestrant
Drug: Neratinib
Drug: Alpelisib
Drug: Everolimus
Drug: Abemaciclib

First Posted Date: 2023-07-06

Last Posted Date: 2023-10-26

Lead Sponsor: Dartmouth-Hitchcock Medical Center

Target Recruit Count: 135

Registration Number: NCT05933395

Locations: 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Phase 3

Recruiting

Conditions: Thymus Neoplasms
Neuroendocrine Tumors
Lung Neuroendocrine Neoplasm

Interventions: Drug: 177Lu-edotreotide
Drug: Everolimus

First Posted Date: 2023-06-26

Last Posted Date: 2024-11-11

Lead Sponsor: Grupo Espanol de Tumores Neuroendocrinos

Target Recruit Count: 120

Registration Number: NCT05918302

Locations: 🇫🇷
Centre Hospitalier Universitaire (CHU) Bordeux, Bourdeaux, France
🇫🇷
Hospital Center University Dijon Bourgogne (CHU Bourgogne), Dijon, France
🇫🇷
Lille University Hospital, Lille, France

and more 23 locations

Study of Ribociclib and Everolimus in HGG and DIPG

Phase 2

Recruiting

Conditions: Glioblastoma
WHO Grade III Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
High Grade Glioma
Diffuse Intrinsic Pontine Glioma
Anaplastic Astrocytoma
Glioblastoma Multiforme
Metastatic Brain Tumor
WHO Grade IV Glioma

Interventions: Drug: Ribociclib
Drug: Everolimus

First Posted Date: 2023-05-06

Last Posted Date: 2024-10-21

Lead Sponsor: Nationwide Children's Hospital

Target Recruit Count: 100

Registration Number: NCT05843253

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 15 locations

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus Everolimus in Patients With Metastatic Unresectable Midgut Neuroendocrine Tumors, NET RETREAT Trial

Phase 2

Recruiting

Conditions: Metastatic Midgut Neuroendocrine Tumor G1
Metastatic Midgut Neuroendocrine Tumor
Metastatic Midgut Neuroendocrine Tumor G2
Unresectable Midgut Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Drug: Everolimus
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2023-03-17

Last Posted Date: 2024-12-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT05773274

Locations: 🇺🇸
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States

and more 16 locations